Brathmòr is inspired by the Scottish Gaelic words brath (a hint, sign, or indication) and mòr (great). Together, they embody the essence of a powerful idea: the moment of inspiration that sparks something extraordinary. At Brathmòr, we believe in the potential of every great idea to transform, innovate, and inspire. Our name reflects our commitment to fostering bold visions and pioneering solutions, rooted in creativity and driven by purpose. Just as a simple sign can lead to a momentous change, Brathmòr is here to turn brilliant ideas into impactful realities.

Brathmòr was stablished in 2013 to support the growth of innovative businesses from start-ups to established ventures with global sales.

We are a dynamic organisation deeply rooted in innovation and leadership. Our strength lies in our comprehensive expertise in the life sciences industry, where we focus on advanced therapies. We specialise in developing and implementing strategic plans, allowing us to advance groundbreaking therapies from concepts to late-stage clinical development.

Our story begins with a small team, united by a shared vision. Over time, this network has grown and our collective knowledge has deepened, enabling us to take the lead in business development and leadership. Our growth trajectory is driven by our shared passion to enhance patient outcomes through breakthrough innovations. Key achievements on our journey include the successful acquisition of substantial funding, assembling a highly skilled team of operational professionals, and leading the development of industry-leading products from discovery through to commercialisation.

Our experience as skilled negotiators has helped us secure profitable co-development and licensing deals with key players in the cell and gene therapies industry. These strategic partnerships have been integral to our journey, catalysing our clients’ business expansion and the development of valuable advanced cell therapy assets and innovative platform technologies.

Beyond our focus on advanced therapies, we lend our expertise to early-stage life science companies, particularly during their Seed and Series A funding cycles. 

Our voyage has also led us to explore the medical food/FSMP sector. Here, we have successfully developed, marketed, and distributed advanced milk-based nutritional products, expanding our reach and enabling us to connect with new markets. In the nutritional sector, our experience has empowered us to identify and develop products that boast exceptional health benefits, bridging the gap between science and nature to enrich people’s lives.

We remain steadfast in our commitment to identifying investment opportunities that align with our mission and goals. This approach has led us to actively scout, analyse, and evaluate potential investment prospects, leading to significant funding accomplishments. Our commitment to investment and business growth has been demonstrated through our successful funding acquisitions for biotech initiatives and our development of novel diagnostic technologies.

Our beginnings were humble, starting with contributions to research projects aimed at understanding various biological and immunological processes. Our journey has been diverse, ranging from involvement in major cell & gene GMP infrastructure projects to driving innovation in the life sciences, securing venture capital funding, and establishing new business divisions.

In the ever-evolving landscape of life sciences, we remain adaptable and forward-thinking. Our vision is to drive growth and make a meaningful difference in patient outcomes through innovative technologies. As we forge ahead, we stay committed to advancing breakthrough therapies and delivering better treatment options to patients worldwide.